Dubai, 24th January, 2017 - MCI is proud to announce the sixth edition of the Asia Pacific Breast Cancer Summit (APBCS) to be held inHong Kong from 17–19 February 2017.
During the past five years, the APBCS has been has been addressing vital topics regarding this prevalent disease and exploring the vast array of molecular technologies, imaging and treatments, including application to patients. APBCS is a unique platform for attendees in bringing up multidisciplinary care concept for breast cancer care and management. The scientific program is developed for patients and patient advocacy groups to expand education and increase awareness on advanced breast cancer, which differs in many ways from breast cancer in the early days. New treatment paradigms are required that integrate elements of prediction, prevention, and management to make care more efficient.
According to the International Agency for Research on Cancer (IARC), just over 400,000 cases were diagnosed in the region out of a total of 1.7 million globally in 2012 and continuously increasing since then.Among females, breast cancer is the highest incident cancer in 7 countries - Indonesia, Japan, Malaysia, Philippines, Singapore, Sri Lanka, and Taiwan.In the recent report of theEconomist -Intelligence Unit (EIU), breast cancer is now a major healthcare issue across Asia-Pacific.Although the incidence of breast cancer in Asian women is still lower than in their western counterparts across all age groups, the disease is drastically increasing in Asian populations. Rapid lifestyle changes is one of the major causes of breast cancer in younger Asian population. Healthy lifestyles, awareness and early screening would reduce breast cancer risks.
The two-day summit aims to drive meaningful discussions - ranging from breast cancer management to aspects of clinical care such as surgery, radiation and oncology under the theme "Reaching New Heights in Breast Cancer Care". The CME/CNE accredited conferencewill have more enriched program for delegates that includes a workshop on the Advances in Aesthetic Outcome in Breast Surgery and Breast Ultrasound and an Introductory Course of Hereditary Breast and Ovarian Cancer Syndromes.The conference will discuss some hot issues and topicsincluding the art of plastic surgery, the difference and lessons learned on breast cancer in Asian womenand the novel future of Oncology therapy.
More than 70 top cancer experts will converge under one roof from Korea, Thailand, Hong Kong, Singapore, Japan, UK, UAE and USA andmore than 500 participants are expected to attendfrom around the world. Regional and international organizations have extended their continued support including Breast Surgery International, Hong Kong Hereditary Breast Cancer Family Registry, The University of Hong Kong, Singapore Society of Oncology, The Hong Kong Cancer Therapy Society, The Hong Kong Breast Oncology Group (HKBOG), The Hong Kong Society of Breast Surgeons, and Hong Kong Society of Clinical Oncology among others.
For more information, please visit www.breastsummit.org.
MCI is a global leader in engaging and activating audiences. Since 1987 we have been driving innovation in events and production, meetings, incentives, congresses and association and community management. Through our creative, consulting, analytics, sustainability and digital services, MCI helps multinational companies and internal associations enhance their organizational performance, grow globally, energise communities and drive their business results. MCI is an independently owned company with headquarters in Geneva, Switzerland. Our 1,800 professionals in 60 cities and 32 countries help clients across Europe, the Americas, Asia-Pacific, India, the Middle East and Africa. Find out more at www.mci-group.com.
MCI Middle East
+971 4 311 6300